氟喹诺酮-复方磺胺甲噁唑联合治疗阴沟肠杆菌引起的骨与关节感染。
Treatment of bone and joint infections caused by Enterobacter cloacae with a fluoroquinolone-cotrimoxazole combination.
机构信息
Department of Internal Medicine and Infectious Diseases, Reims Teaching Hospitals, Reims, France.
Department of Bacteriology, Reims Teaching Hospitals, Reims, France.
出版信息
Int J Antimicrob Agents. 2019 Aug;54(2):245-248. doi: 10.1016/j.ijantimicag.2019.05.010. Epub 2019 May 13.
Although the frequency of bone and joint infections caused by Enterobacter spp. is increasing, studies regarding the optimal antibiotic therapy are scarce. The objective of this retrospective study was to assess the clinical outcomes and safety of a fluoroquinolone-cotrimoxazole combination for the treatment of bone and joint infections caused by Enterobacter cloacae. Between 2010 and 2017, 30 patients with bone and joint infections caused by E. cloacae were treated with a fluoroquinolone-cotrimoxazole combination for 8-12 weeks. There were 26 cases (87%) of infection of an internal fixation device, two cases (6.6%) of pseudarthrosis with chronic osteomyelitis, and two cases (6.6%) of infection of knee and ankle prosthetic devices. The cure rate of the fluoroquinolone-cotrimoxazole combination was 80% by intention-to-treat analysis, with a mean follow-up of 29.3 ± 19.1 months. The fluoroquinolone-cotrimoxazole combination for 8-12 weeks is effective for the treatment of bone and joint infections caused by E. cloacae.
虽然肠杆菌属引起的骨和关节感染的频率正在增加，但关于最佳抗生素治疗的研究却很少。本回顾性研究的目的是评估氟喹诺酮-复方磺胺甲噁唑联合治疗阴沟肠杆菌引起的骨和关节感染的临床疗效和安全性。2010 年至 2017 年间，30 例阴沟肠杆菌引起的骨和关节感染患者接受氟喹诺酮-复方磺胺甲噁唑联合治疗 8-12 周。26 例（87%）为内置固定装置感染，2 例（6.6%）为假关节合并慢性骨髓炎，2 例（6.6%）为膝和踝关节假体装置感染。意向治疗分析中氟喹诺酮-复方磺胺甲噁唑联合治疗的治愈率为 80%，平均随访 29.3±19.1 个月。氟喹诺酮-复方磺胺甲噁唑联合治疗 8-12 周可有效治疗阴沟肠杆菌引起的骨和关节感染。
Zotero 插件